TD Asset Management
MPLT

TD Asset Management’s MapLight Therapeutics MPLT Stock Holding History

TD Asset Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
54,526
+6,758
+14% +$194K ﹤0.01% 979
2026
Q1 		$971K Buy
47,768
+10,808
+29% +$193K ﹤0.01% 1098
2025
Q4 		$649K Buy
+36,960
New +$619K ﹤0.01% 1149

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TD Asset Management's MPLT Position: Q2 2026 in Review

TD Asset Management increased its MapLight Therapeutics (MPLT) stake by 14% in Q2 2026, buying an estimated $194K and bringing the position to 54,526 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #979.

TD Asset Management first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • TD Asset Management held 54,526 shares of MapLight Therapeutics worth $1.95M as of Q2 2026.
  • TD Asset Management bought 6,758 MapLight Therapeutics shares in Q2 2026, an estimated $194K.
  • MapLight Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #979 holding.
  • TD Asset Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.